Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-445-8 | CAS number: 1326-83-6 This substance is identified in the Colour Index by Colour Index Constitution Number, C.I. 53186.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In an in vivo local lymphnode assay (LLNA) according to OECD 429, the test item did not show skin sensitising properties.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 04 December, 2017 - 08 January, 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- 22 July 2010
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- 20 July 2012
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
- Specific details on test material used for the study:
- Expiry date: November 30, 2021
- Species:
- mouse
- Strain:
- CBA/Ca
- Remarks:
- CBA/Ca Ola Hsd mice (SPF)
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: TOXI-COOP ZRT., H-1103, Budapest, Cserkesz u. 90. Hungary
- Females nulliparous and non-pregnant: yes
- Microbiological status of animals, when known: Hygienic level at arrival was SPF; Hygienic level during the study was good conventional.
- Age at study initiation: Young adult mice; 11 weeks old (at start of the main test)
- Weight at study initiation: 19.1 – 23.4 g (the weight variation in animals involved in the study did not exceed ± 20 % of the mean weight)
- Housing during the test: Grouped caging (4 animals/cage) in Type II cages
- Diet: ssniff® Rat/Souris-Elevage E complete diet for rats and mice produced by ssniff Spezialdiäten GmbH, D-59494 Soest Germany, ad libitum
- Water: tap water from watering bottles ad libitum
- Acclimation period: 7 days
- Indication of any skin lesions: Only healthy animals (and not showing any sign of skin lesion) were used
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 30 – 70
- Photoperiod (hrs dark / hrs light): 12/12 (from 6.00 a.m. to 6.00 p.m.) - Vehicle:
- other: Pluronic®PE 9200 (Plu)
- Concentration:
- 25 %, 10 %, 5 % and 2.5 % (w/w) as suspension in Plu
- No. of animals per dose:
- 4 animals/dose group
- Details on study design:
- MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method:
LLNA
- Criteria used to consider a positive response:
The test item is considered as a skin sensitizer, if:
Exposure to at least one concentration of the test item resulted in an incorporation of 3HTdR at least 3-fold or greater than recorded in control mice, as indicated by the stimulation index (SI ≥ 3). However, the strength of the dose-response, the statistical significance and the consistency of the solvent/vehicle and positive control responses may also be used when determining whether a borderline result is declared positive.
TREATMENT PREPARATION AND ADMINISTRATION:
Each mouse was topically treated with 25 µL of the appropriate formulations of the test item, the positive control substance or the vehicles using a pipette, on the dorsal surface of each ear. After the treatments animals were returned to their cages. Each animal was dosed once a day for three consecutive days (Days 1, 2 and 3). There was no treatment on Days 4, 5 and 6. Individual body weights were recorded on Day 1 (beginning of the test) and on Day 6. During the main test (from Day 1 to Day 6) all animals were observed at least once a day for any clinical signs, including systemic toxicity and local irritation. Irritation was monitored by erythema scoring during the whole test. Individual records were maintained.
Injection of 3HTdR
On Day 6 each mouse was intravenously injected via the tail vein with 250 µL of sterile PBS (1 x PBS, diluted from 10x concentrate) containing approximately 20 µCi of 3H-methyl-thymidine using a hypodermic needle with 1 mL sterile syringe. Once injected, mice were left for 5 hours (± 30 minutes).
Removal and Preparation of Draining Auricular Lymph Nodes
Five hours (± 30 minutes) after intravenous injection the mice were sacrificed by cervical dislocation. The draining auricular lymph nodes were excised by making a small incision in the skin between the jaw and the sternum, pulling the skin gently back towards the ears and exposing the lymph nodes. Then the nodes were removed using forceps. Once removed, the nodes of the mice from each test group were pooled and collected separately in a Petri dish containing a small amount (1-2 mL) of PBS to keep the nodes wet before processing.
Preparation of Single Cell Suspension of Lymph Node Cells
A single cell suspension (SCS) of lymph node cells (LNCs), pooled according to groups, was prepared and collected in disposable tubes by gentle mechanical disaggregating of the lymph nodes through a cell strainer using the plunger of a disposable syringe. The cell strainer was washed with PBS (up to 10 mL). LNCs were pelleted with a relative centrifugal force (RCF) of approximately 190 x g for 10 minutes at 4 °C. After centrifugation, the supernatant was removed, leaving 1-2 mL supernatant above each pellet. The pellets were gently agitated before making up to 10 mL with PBS and re-suspending the LNCs. The washing procedure was repeated twice. This procedure was repeated for each group of pooled lymph nodes.
Determination of Incorporated 3HTdR
After the final wash, each supernatant was removed leaving a small volume (< 0.5 mL) of supernatant above each pellet. The pellets were gently agitated before suspending the LNCs in 3 mL of 5 % (w/v) trichloroacetic acid (TCA, dissolved in purified water) for precipitation of the macromolecules. After incubation with 5 % TCA at 2-8 °C overnight (ca. 18 hrs), each precipitate was removed by centrifugation of the samples at approximately 190 x g for 10 minutes at 4 °C and decanting the supernatants, than the pellets were re-suspended in 1 mL of 5 % TCA and dispersed using an ultrasonic water bath. Samples were transferred to suitable sized scintillation vials containing 10 mL of scintillation liquid, gently mixed and loaded into the beta-scintillation counter. 3HTdR incorporation was measured for up to 10 minutes per sample. The beta-counter expressed the 3HTdR incorporation as the amount of radioactive disintegration per minute (DPM). Similarly, background 3HTdR levels were measured in two 1 mL aliquots of 5 % TCA. Instrument used for the measurement: Tri-Carb 3100TR Liquid Scintillation Analyzer, Serial Number: 072971
DPM (disintegration per minute) was measured for each treatment group. The measured DPM values were corrected with the background DPM value: the average of the two measured DPM values of 5 % (w/v) TCA solutions was used as the background DPM value. The results were expressed as DPM/mouse. The stimulation index (SI = the DPM/mouse of a treated (positive control or test item) group divided by the DPM/mouse of the respective negative control group) for each treatment group was also calculated. A stimulation index of 3 or greater is an indication of a positive result. Dose-response relationship was evaluated by linear regression using SI values. All calculations were made by Microsoft Excel Software. Based on the results no EC3 value (dose calculated to induce a stimulation index of 3) was calculated for the test item. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- The randomization was checked by computer software [SPSS/PC+ (4.0.1)] according to the actual body weights verifying the homogeneity and deviations between the groups.
- Positive control results:
- The positive control group animals were treated with 25 % (w/v) HCA solution (formulated in AOO) concurrent to the test item groups. No mortality, cutaneous reactions or signs of toxicity were observed in the positive control group.
A significant lymphoproliferative response (SI ≥ 3) was noted for HCA (SI = 9.5). The results of the positive control item demonstrated an appropriate performance of the test in accordance with the relevant guidelines and confirmed the validity of the assay. - Key result
- Parameter:
- SI
- Value:
- 0.5
- Variability:
- p = 0.63, r = 0.37
- Test group / Remarks:
- test item concentration of 25 %
- Remarks on result:
- other: No significant dose-response relationship was observed.
- Key result
- Parameter:
- SI
- Value:
- 0.5
- Variability:
- p = 0.63, r = 0.37
- Test group / Remarks:
- test item concentration of 10 %
- Remarks on result:
- other: No significant dose-response relationship was observed
- Key result
- Parameter:
- SI
- Value:
- 0.6
- Variability:
- p = 0.63, r = 0.37
- Test group / Remarks:
- test item concentration of 5 %.
- Remarks on result:
- other: No significant dose-response relationship was observed
- Key result
- Parameter:
- SI
- Value:
- 0.5
- Variability:
- p = 0.63, r = 0.37
- Test group / Remarks:
- at test item concentration of 2.5 % (w/w)
- Remarks on result:
- other: No significant dose-response relationship was observed
- Cellular proliferation data / Observations:
- CELLULAR PROLIFERATION DATA
No significant lymphoproliferative response (SI ≥ 3) compared to the concurrent control (Plu) was noted for Solubilised Sulphur Black 1 at the applied test concentrations. The observed stimulation index values were 0.5, 0.5, 0.6 and 0.5 at test item concentrations of 25 %, 10 %, 5 % and 2.5 % (w/w), respectively. Significance of the dose-response was evaluated by linear regression using the SI values. No significant dose-related response was observed (p = 0.63, r = 0.37). Visually larger lymph nodes compared to the relevant vehicle control (AOO) were observed in the positive control group only. The appearance of the lymph nodes were normal in both negative (vehicle) control groups and in the test item treated groups.
DETAILS ON STIMULATION INDEX CALCULATION
No significant lymphoproliferative response (SI > 3) compared to the relevant vehicle control (Plu) was noted for the test item at the tested concentrations. The observed stimulation index values were 0.5, 0.5, 0.6 and 0.5 at test item concentrations of 25 %, 10 %, 5 % and 2.5 % (w/w), respectively. No dose-related response was observed.
EC3 CALCULATION
not determinable
CLINICAL OBSERVATIONS:
No mortality or symptoms of systemic toxicity were observed in any treatment group. No sign of irritation (indicated by an erythema score > 3) or any other local effect were observed in any treatment group. Dark colour of the test item formulations (black) made observation of erythema difficult on the first treatment day in the 25 % and in the 10 % (w/w) dose groups. Test item residual was also observed in the 25 % (w/w) dose group on Days 2 and 3 and in the 10 % (w/w) dose group on Day 2 (after the treatments), but it was not significant and did not interfere the observation of signs of irritation on these days. It is unlikely that an erythema of No mortality or symptoms of systemic toxicity were observed in any treatment group. No sign of irritation (indicated by an erythema score > 3) occurred during the test.
BODY WEIGHTS
Body weight decrease by > 5 % was observed in the 25 % and in the 5 % (w/w) dose groups (1 of the 4 animals with 6 % decrease in both groups). The effect was not dose dependent and was not considered relevant as the mean values did not decrease significantly. No body weight decrease by > 5 % was observed in the other groups. - Interpretation of results:
- GHS criteria not met
- Conclusions:
- In an in vivo local lymphnode assay (LLNA) according to OECD 429, the test item did not show skin sensitising properties.
- Executive summary:
The aim of this study was to evaluate the skin sensitization potential of the test item following dermal exposure in the Local Lymph Node Assay according to OECD guideline 429. Preliminary tests were performed to find an appropriate vehicle and the maximum applicable concentration. Solubility of the test item in vehicles preferred in the LLNA was evaluated. Based on the results the test item was formulated in inaqueous 1 % (w/v) Pluronic®PE 9200 (Plu) in the main test. The maximum achievable concentration (based on solubility) was 25 % (w/w). According to the results of the DRF (no adverse effects were observed up to this maximum concentration) the test item was examined in the main test in concentrations of 25 %, 10 %, 5 % and 2.5 % (w/w) as suspension formulations in Plu. Appropriate positive control (a-Hexylcinnamaldehyde, HCA), furthermore two negative control groups (vehicles of the test and positive control groups, respectively), were employed. The positive control item (25 % (w/v) HCA in Acetone:Olive oil 4:1 (v/v) mixture, AOO) induced significant stimulation over the relevant control (SI = 9.5) thus confirming the validity of the assay.
No mortality was observed during the main test. No significant, treatment related effect on body weights or any other sign of systemic toxicity were observed in any treatment group. No signs of irritation (monitored by erythema scoring) or any other local effect were observed at the treatment site (ears) in any treatment group. No significantly increased lymphoproliferation (indicated by an SI of above 3) compared to the relevant control (Plu) was noted for the test item at the applied test concentrations. The observed stimulation index values were 0.5, 0.5, 0.6 and 0.5 at test item concentrations of 25 %, 10 %, 5 % and 2.5 % (w/w), respectively. No significant dose-response relationship was observed (p = 0.63, r = 0.37; evaluated by linear regression using SI values). According to the evaluation, the lack of a significantly increased lymphoproliferation (indicated by an SI of above 3) up to the maximum attainable concentration of 25 % (w/w), based on solubility) and also the lack of a significant dose-response relationship are considered evidence that the test item is not a skin-sensitizer.
Reference
Table 3: Individual Body Weights of the Animals with Group Means and the Body Weight Changes in the Dose Range Finding Test
Animal |
Dose Group |
Initial Body |
Terminal Body |
Body Weight |
Number |
Weight (g) |
Weight (g)* |
Change (%) |
|
23 |
Solubilised Sulphur Black 1 |
18.5 |
21.3 |
15 |
24 |
25 % in Plu |
19.5 |
21.4 |
10 |
Mean |
19.0 |
21.4 |
12 |
|
25 |
Solubilised Sulphur Black 1 |
18.4 |
21.0 |
14 |
26 |
10 % in Plu |
19.8 |
21.7 |
10 |
Mean |
19.1 |
21.4 |
12 |
*Terminal body weights were measured on Day 6.
Table 4: Clinical Observations in the Dose Range Finding Test
Dose Group |
Animal Number |
Days |
||||||||
1 |
2 |
3 |
4 |
5 |
6 |
|||||
PT |
AT |
PT |
AT |
PT |
AT |
|||||
Solubilised Sulphur Black 1 |
23 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
24 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
Solubilised Sulphur Black 1 |
25 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
26 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
T = Treatment
PT = Prior to the treatment
AT = After the treatment
Plu= aqueous 1 % (w/v) Pluronic®PE 9200
N = Normal (no sign of toxicity observed)
Table 5: Erythema Scores in the Dose Range Finding Test
Dose Group |
Animal Number |
Ears |
Days |
||||||||
1 |
2 |
3 |
4 |
5 |
6 |
||||||
PT |
AT |
PT |
AT |
PT |
AT |
||||||
Solubilised Sulphur Black 1 |
23 |
L |
0 |
NO |
0 |
NO |
0 |
NO |
0 |
0 |
0 |
R |
0 |
NO |
0 |
NO |
0 |
NO |
0 |
0 |
0 |
||
24 |
L |
0 |
NO |
0 |
NO |
0 |
NO |
0 |
0 |
0 |
|
R |
0 |
NO |
0 |
NO |
0 |
NO |
0 |
0 |
0 |
||
Solubilised Sulphur Black 1 |
25 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
26 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
L = Left R = Right
PT = Prior to the treatment AT = After the treatment
Plu= aqueous 1 % (w/v) Pluronic®PE 9200
NO = Not observable (any erythema is hidden by dark colour of the test item formulation)
Table 6: Individual Ear Thickness Values and the Deviations from the Initial Values in the Dose Range Finding Test
Dose Group |
Animal |
Ears |
Day 1* |
Day 3$ |
Day 3 |
Day 6# |
Day 6 |
|
Number |
value (mm) |
value (mm) |
% deviation |
value (mm) |
% deviation |
|
|
23 |
L |
0.19 |
0.19 |
0.0 |
0.19 |
0.0 |
Solubilised Sulphur Black 1 |
R |
0.19 |
0.19 |
0.0 |
0.19 |
0.0 |
|
25 % in Plu |
24 |
L |
0.20 |
0.19 |
-5.0 |
0.19 |
-5.0 |
|
R |
0.20 |
0.19 |
-5.0 |
0.19 |
-5.0 |
|
|
25 |
L |
0.19 |
0.19 |
0.0 |
0.19 |
0.0 |
Solubilised Sulphur Black 1 |
R |
0.19 |
0.19 |
0.0 |
0.19 |
0.0 |
|
10 % in Plu |
26 |
L |
0.20 |
0.20 |
0.0 |
0.19 |
-5.0 |
|
R |
0.20 |
0.20 |
0.0 |
0.19 |
-5.0 |
L = Left
R = Right
Plu= aqueous 1 % (w/v) Pluronic®PE 9200
* Ear thickness was measured prior to the first treatment.
$ Ear thickness was measured approximately 48 hours after the first treatment (prior to the third treatment).
# Ear thickness was measured at the end of the test.
Table 7: Individual Body Weights of the Animals with Group Means, the Associated Error Termsand Body Weight Changes in the Main Test
Animal |
Dose Group |
Initial |
Terminal |
Body Weight |
Number |
Body Weight |
Body Weight |
Change |
|
(g) |
(g) |
(%) |
||
38 |
Vehicle control |
20.1 |
19.2 |
-4 |
39 |
for the positive control: |
20.5 |
20.4 |
0 |
40 |
AOO |
23.4 |
22.4 |
-4 |
41 |
|
22.0 |
21.6 |
-2 |
|
Mean |
21.5 |
20.9 |
-3 |
|
SD |
1.5 |
1.4 |
|
42 |
Positive control: |
20.1 |
20.2 |
0 |
43 |
25 % HCA |
20.8 |
20.4 |
-2 |
44 |
in AOO |
21.3 |
20.8 |
-2 |
45 |
|
23.1 |
23.1 |
0 |
|
Mean |
21.3 |
21.1 |
-1 |
|
SD |
1.3 |
1.3 |
|
86 |
Vehicle control |
21.2 |
21.4 |
1 |
87 |
for the test item: |
19.9 |
18.9 |
-5 |
88 |
Plu |
21.9 |
21.8 |
0 |
89 |
|
22.4 |
21.8 |
-3 |
|
Mean |
21.4 |
21.0 |
-2 |
|
SD |
1.1 |
1.4 |
|
90 |
Solubilised Sulphur Black 1 |
21.7 |
21.7 |
0 |
91 |
25 % |
19.7 |
19.5 |
-1 |
92 |
in Plu |
21.0 |
20.5 |
-2 |
93 |
|
22.7 |
21.4 |
-6 |
|
Mean |
21.3 |
20.8 |
-2 |
|
SD |
1.3 |
1.0 |
|
94 |
Solubilised Sulphur Black 1 |
21.6 |
21.1 |
-2 |
95 |
10 % |
19.3 |
18.9 |
-2 |
96 |
in Plu |
21.0 |
20.9 |
0 |
97 |
|
22.4 |
21.8 |
-3 |
|
Mean |
21.1 |
20.7 |
-2 |
|
SD |
1.3 |
1.2 |
|
98 |
Solubilised Sulphur Black 1 |
19.1 |
18.9 |
-1 |
99 |
5 % |
21.8 |
21.4 |
-2 |
100 |
in Plu |
22.1 |
20.7 |
-6 |
101 |
|
21.2 |
21.5 |
1 |
|
Mean |
21.1 |
20.6 |
-2 |
|
SD |
1.4 |
1.2 |
|
102 |
Solubilised Sulphur Black 1 |
21.7 |
21.4 |
-1 |
103 |
2.5 % |
19.2 |
18.5 |
-4 |
104 |
in Plu |
22.1 |
21.4 |
-3 |
105 |
|
21.2 |
20.6 |
-3 |
|
Mean |
21.1 |
20.5 |
-3 |
|
SD |
1.3 |
1.4 |
|
HCA =a-Hexylcinnamaldehyde AOO = Acetone: Olive oil 4:1 (v/v) mixture
Plu= aqueous 1 % (w/v) Pluronic®PE 9200 SD = Standard Deviation
Table 8: Clinical Observations in the Main Test
Dose Group |
Animal |
Days |
||||||||
1 |
2 |
3 |
4 |
5 |
6 |
|||||
PT |
AT |
PT |
AT |
PT |
AT |
|||||
Vehicle control for the positive control: |
38 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
39 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
40 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
41 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
Positive control: 25 % HCA in AOO |
42 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
43 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
44 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
45 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
Vehicle control for the test item: Plu |
86 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
87 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
88 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
89 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
Solubilised Sulphur Black 1 |
90 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
91 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
92 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
93 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
Solubilised Sulphur Black 1 |
94 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
95 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
96 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
97 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
Solubilised Sulphur Black 1 |
98 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
99 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
100 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
101 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
Solubilised Sulphur Black 1 |
102 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
103 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
104 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
|
105 |
N |
N |
N |
N |
N |
N |
N |
N |
N |
PT = Prior to the treatment
AT = After the treatment
HCA =a-Hexylcinnamaldehyde
AOO = Acetone: Olive oil 4:1 mixture (v/v)
Plu= aqueous 1 % (w/v) Pluronic®PE 9200
N = Normal (no symptoms observed)
Table 9: Erythema Scores in the Main Test
Dose Group |
Animal Number |
Ears |
Days |
||||||||
1 |
2 |
3 |
4 |
5 |
6 |
||||||
PT |
AT |
PT |
AT |
PT |
AT |
||||||
Vehicle control for the positive control: |
38 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
39 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
40 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
41 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Positive control: |
42 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
43 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
44 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
45 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Vehicle control for the test item: |
86 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
87 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
88 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
89 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Solubilised Sulphur Black 1 |
90 |
L |
0 |
NO |
0 |
0* |
0 |
0* |
0 |
0 |
0 |
R |
0 |
NO |
0 |
0* |
0 |
0* |
0 |
0 |
0 |
||
91 |
L |
0 |
NO |
0 |
0* |
0 |
0* |
0 |
0 |
0 |
|
R |
0 |
NO |
0 |
0* |
0 |
0* |
0 |
0 |
0 |
||
92 |
L |
0 |
NO |
0 |
0* |
0 |
0* |
0 |
0 |
0 |
|
R |
0 |
NO |
0 |
0* |
0 |
0* |
0 |
0 |
0 |
||
93 |
L |
0 |
NO |
0 |
0* |
0 |
0* |
0 |
0 |
0 |
|
R |
0 |
NO |
0 |
0* |
0 |
0* |
0 |
0 |
0 |
||
Solubilised Sulphur Black 1 |
94 |
L |
0 |
NO |
0 |
0* |
0 |
0 |
0 |
0 |
0 |
R |
0 |
NO |
0 |
0* |
0 |
0 |
0 |
0 |
0 |
||
95 |
L |
0 |
NO |
0 |
0* |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
NO |
0 |
0* |
0 |
0 |
0 |
0 |
0 |
||
96 |
L |
0 |
NO |
0 |
0* |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
NO |
0 |
0* |
0 |
0 |
0 |
0 |
0 |
||
97 |
L |
0 |
NO |
0 |
0* |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
NO |
0 |
0* |
0 |
0 |
0 |
0 |
0 |
||
Solubilised Sulphur Black 1 |
98 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
99 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
100 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
101 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Solubilised Sulphur Black 1 |
102 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
103 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
104 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
105 |
L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
R |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
L = Left R = Right PT = Prior to treatment AT = After the treatment
AOO = Acetone: Olive oil 4:1 (v/v) mixture HCA =a-Hexylcinnamaldehyde Plu= aqueous 1 % (w/v) Pluronic®PE 9200
* Test Item residual is observed on the ears NO = Not observable (any erythema is hidden by dark colour of the test item formulation)
Table 10: Visual Observations of the Lymph Nodes in the Main Test
Dose Group |
Animal |
Appearance of Lymph Nodes |
Vehicle control for the positive control: |
38 |
N |
39 |
N |
|
40 |
N |
|
41 |
N |
|
Positive control: |
42 |
Larger than the relevant control (AOO) |
43 |
Larger than the relevant control (AOO) |
|
44 |
Larger than the relevant control (AOO) |
|
45 |
Larger than the relevant control (AOO) |
|
Vehicle control for the test item: |
86 |
N |
87 |
N |
|
88 |
N |
|
89 |
N |
|
Solubilised Sulphur Black 1 |
90 |
N |
91 |
N |
|
92 |
N |
|
93 |
N |
|
Solubilised Sulphur Black 1 |
94 |
N |
95 |
N |
|
96 |
N |
|
97 |
N |
|
Solubilised Sulphur Black 1 |
98 |
N |
99 |
N |
|
100 |
N |
|
101 |
N |
|
Solubilised Sulphur Black 1 |
102 |
N |
103 |
N |
|
104 |
N |
|
105 |
N |
AOO = Acetone: Olive oil 4:1 (v/v) mixture
HCA =a-Hexylcinnamaldehyde
Plu= aqueous 1 % (w/v)Pluronic®PE 9200
N = Normal
Table 11: DPM and Stimulation Index Values for all Groups in the Main Test
Dose Group |
Measured |
Group* |
DPM/Mouse# |
Stimulation |
DPM/group |
DPM |
Index Values |
||
Vehicle control for the positive control: |
8360 |
8335.5 |
2083.9 |
1.0 |
AOO |
|
|
|
|
Positive control: |
78929 |
78904.5 |
19726.1 |
9.5 |
25 % HCA in AOO |
|
|
|
|
Vehicle control for the test item: |
3549 |
3524.5 |
881.1 |
1.0 |
Plu |
|
|
|
|
Solubilised Sulphur Black 1 |
1776 |
1751.5 |
437.9 |
0.5 |
25 % in Plu |
|
|
|
|
Solubilised Sulphur Black 1 |
1676 |
1651.5 |
412.9 |
0.5 |
10 % in Plu |
|
|
|
|
Solubilised Sulphur Black 1 |
2308 |
2283.5 |
570.9 |
0.6 |
5 % in Plu |
|
|
|
|
Solubilised Sulphur Black 1 |
1879 |
1854.5 |
463.6 |
0.5 |
2.5 % in Plu |
|
|
|
|
HCA =a-Hexylcinnamaldehyde
AOO = Acetone: Olive oil 4:1 (v/v) mixture
Plu= aqueous 1 % (w/v) Pluronic®PE 9200
*Group DPM = measured DPMgroup- average DPMbackground
Average DPMbackground= 24.5
# Number of animals/group = 4
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
The aim of this study was to evaluate the skin sensitization potential of the test item following dermal exposure in the Local Lymph Node Assay according to OECD guideline 429. Preliminary tests were performed to find an appropriate vehicle and the maximum applicable concentration. Based on the results the test item was formulated in inaqueous 1 % (w/v) Pluronic®PE 9200 (Plu) in the main test. The maximum achievable concentration (based on solubility) was 25 % (w/w). According to the results of the DRF (no adverse effects were observed up to this maximum concentration) the test item was examined in the main test in concentrations of 25 %, 10 %, 5 % and 2.5 % (w/w) as suspension formulations in Plu. Appropriate positive control (a-Hexylcinnamaldehyde, HCA), furthermore two negative control groups (vehicles of the test and positive control groups, respectively), were employed. The positive control item (25 % (w/v) HCA in Acetone:Olive oil 4:1 (v/v) mixture, AOO) induced significant stimulation over the relevant control (SI = 9.5) thus confirming the validity of the assay.
No mortality was observed during the main test. No significant, treatment related effect on body weights or any other sign of systemic toxicity were observed in any treatment group. No signs of irritation (monitored by erythema scoring) or any other local effect were observed at the treatment site (ears) in any treatment group. No significantly increased lymphoproliferation (indicated by an SI of above 3) compared to the relevant control (Plu) was noted for the test item at the applied test concentrations. The observed stimulation index values were 0.5, 0.5, 0.6 and 0.5 at test item concentrations of 25 %, 10 %, 5 % and 2.5 % (w/w), respectively. No significant dose-response relationship was observed (p = 0.63, r = 0.37; evaluated by linear regression using SI values). According to the evaluation, the lack of a significantly increased lymphoproliferation (indicated by an SI of above 3) up to the maximum attainable concentration of 25 % (w/w), based on solubility) and also the lack of a significant dose-response relationship are considered evidence that the test item is not a skin-sensitizer.
Justification for classification or non-classification
Classification, Labelling, and Packaging
Regulation (EC) No 1272/2008
The available experimental test data are reliable and suitable for
classification purposes under Regulation 1272/2008 (CLP). As a result
the test item is considered not to be classified for skin sensitisation
under Regulation (EC) No 1272/2008, as amended for the twelfth time in
Regulation (EU) No 2019/521.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.